Results for tag: "X Linked Hypophosphatemia Drug"

X Linked Hypophosphatemia (XLH) is a rare genetic disorder that affects the bones and teeth. It is caused by a mutation in the PHEX gene, which is located on the X chromosome. Treatment for XLH typically involves the use of drugs that help to reduce the amount of phosphate in the body. Endocrine and Metabolic Disorders Drugs are used to treat a variety of conditions, including XLH. These drugs work by either blocking the absorption of phosphate from the gut or by increasing the excretion of phosphate from the body. The X Linked Hypophosphatemia Drug market is a specialized segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are specifically designed to treat XLH. These drugs are typically administered orally or intravenously, depending on the severity of the condition. Common drugs used to treat XLH include phosphate binders, calcitriol, and vitamin D analogs. Some companies in the X Linked Hypophosphatemia Drug market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more